Introduction
It has been a decade since the first studies 1,2 of the effects of antipsychotics on brain receptors were reported. Much has been learnt since. The purpose of this article is to synthesize this information. This is not a comprehensive review of PET data on this subject. Instead it represents a selective analysis of the extant data with a view to develop a theoretical perspective and a clinical understanding of the role of the dopamine D 2 and serotinin 5-HT 2 receptors in the treatment of schizophrenia.
Typical antipsychotics, D 2 occupancy and clinical correlates
It has been known for almost two decades that antipsychotic effects and extrapyramidal side effects (as well as catalepsy in animals) are related to the dopamine D 2 blocking properties of antipsychotics. 3, 4 However, prior to the advent of PET imaging it was not possible to observe any of these relationships at a receptor level in vivo in humans. Farde et al 5 reported the first systematic study of the action of antipsychotics on in vivo D 2 receptors and found that typical antipsychotics occupied 70-89% D 2 receptors at conventional clinical doses. Moreover, patients with extrapyramidal sideeffects (EPS) had, on average, higher D 2 occupancy than those who did not exhibit EPS (82% vs 72%). This relationship was further supported by Nordstrom et al 6 who found that those with greater than 60% D 2 occupancy showed much better antipsychotic response than those with occupancies below 60%. These data suggest that there may be a therapeutic window, perhaps between 60% and 80% D 2 occupancy, which may yield adequate antipsychotic response with low or minimal EPS.
In a clinical context, it has been shown that low doses of oral haloperidol, 1-5 mg day −1 (plasma levels of 0.5-5.8 ng ml −1 ) lead to occupancies ranging from 50 to 88%; and that 2 mg day −1 of haloperidol may be sufficient to get most patients into the putatively therapeutic 60-80% occupancy range. 7 To test the clinical validity of this, seven patients, all suffering from a first episode of schizophrenic illness, were treated with haloperidol 2 mg day −1 in an open clinical-PET investigation. 8 The average D 2 receptor occupancy was 67% and significant improvement in positive as well as negative symptoms was observed. 8 This clinical-D 2 occupancy correlation fits rather nicely with McEvoy et al 9 who applied a clinical 'neuroleptic threshold' technique to determine the minimal effective dose. The median threshold dose for the first episode patients was 2.1 mg of haloperidol-and the addition of an extra 5-10 mg day −1 of haloperidol did not significantly augment their clinical response, but did increase the incidence of EPS. Several recent studies by Stone et al, 10 Janicak et al 11 as well as Ortega-Soto et al 12, 13 all point to the effectiveness of low dose antipsychotics (2-5 mg day −1 of haloperidol or equivalent) and uniformly show that higher doses (10-50 mg day −1 ) increase the incidence of EPS-related side-effects without an appreciable change in clinical response.
Even with optimal dosing, a significant number of patients (estimated between 20-50%) do not respond satisfactorily to treatment with D 2 blockers. The cause of this non-response is not known, but non-responders show no difference in their D 2 occupancy profiles. 14, 15 This has led to the suggestion that non-responders to D 2 occupancy may reflect a biologically distinct subset of the illness. 14, 15 In fact Pilowsky et al 16 show that some patients who do not respond despite high and adequate D 2 occupancy, respond to much lower D 2 occupancy with clozapine (which affects several receptor systems in addition to D 2 ). Even those who do respond to the D 2 -mediated mechanism of response usually show less than satisfactory improvement in negative symptoms and cognitive impairment. These limitations of the typical antipsychotics (some patients are refractory, many get EPS, and negative and positive symptom improvement is limited) necessitated the development of 'atypical' antipsychotics.
Atypical antipsychotic, 5-HT 2 and D 2 occupancy, and clinical correlates
While there is no consensus on how to define an atypical antipsychotic, most authorities agree that clozapine (and more recently risperidone, olanzapine and sertindole) are 'atypical'. All four of the above agents are distinguished from typical antipsychotics by one pharmacological commonality: a higher affinity for the 5-HT 2 as opposed to D 2 dopamine receptor in vitro as well as ex vivo in animals. 17, 18 Since reliable neuroimaging data in humans are available only for clozapine and risperidone, this section focuses on these two atypical antipsychotics.
A comprehensive PET study of the receptor profile of clozapine shows that the D 2 occupancy in patients treated with 125-600 mg day −1 of clozapine varied from 20-67%, while at these doses the 5-HT 2 occupancy is always greater than 80%. 19 No patient on clozapine demonstrated D 2 occupancy in the range that is likely to produce EPS (ie 80% or greater). We find similar results in a series of nine patients whose doses ranged from 75-900 mg day −1 (and plasma levels from 107 to 859 ng ml −1 of clozapine). All nine patients exhibit very high 5-HT 2 occupancy (Ͼ90% in all patients, as measured using 18 F-setoperone) and low to modest D 2 dopamine occupancy (24-66% as measured using 11 C-raclopride; preliminary analysis communicated by Dr Robert Zipursky). Similar findings have also been reported by other groups using PET 20 and SPECT 16, 21 (see Pickar et al 21 for the only clozapine patient with Ͼ80% D 2 occupancy using SPECT). Thus at effective doses (between 200-400 mg day −1 ) 22 clozapine occupies significantly fewer D 2 receptors than are occupied by typical antipsychotics and certainly fewer than those associated with EPS.
Risperidone, like clozapine, exhibits high levels of 5-HT 2 occupancy. However, risperidone's D 2 occupancy is clearly higher than that of clozapine. [23] [24] [25] Kapur et al 25 have shown that, on average, 2 mg day
of risperidone occupied 66% of D 2 receptors, 4 mg day −1 occupied 73% while 6 mg day −1 occupied 79%. While most patients with risperidone did not experience EPS, those who did experience EPS had a much higher D 2 occupancy than those who did not (79% ± 4% vs 68% ± 5%). Thus risperidone's high levels of 5-HT 2 occupancy (whatever its other benefits) cannot provide absolute protection from EPS once D 2 blockade is near complete. 25, 26 The putatively negative effects to too much D 2 blockade can also be observed in the multi-centre studies which compared 2-16 mg day −1 of risperidone with 10-20 mg day −1 of haloperidol. 27, 28 Six mg day −1 of risperidone was numerically and statistically superior to haloperidol in terms of positive, negative and EPS syndromes. However, beyond 6 mg day −1 , the positive and negative symptom response decreased and EPS increased, such that risperidone 10-16 mg day −1 was statistically indistinguishable from haloperidol. Doses of risperidone beyond 6 mg day −1 give greater than 80% D 2 occupancy. 25, 29 Thus, it would seem that pushing D 2 occupancy to saturation, in atypical drugs like risperidone, may not only diminish their EPS superiority, but may also decrease their superiority on positive and negative symptoms. Therefore, it is not sufficient that a drug display the 'right 5-HT 2 /D 2 affinity ratio' in the test tube. 17, 18 It is imperative that the drug be used in humans in doses where D 2 occupancy is not saturated. 25 
Beyond the typical/atypical dichotomy: towards a new framework
Until recently, clozapine was the only 'atypical' antipsychotic but several new antipsychotics are available now. They all differ from the typical antipsychotics, but it is increasingly becoming evident that these newer antipsychotics may not replicate all of clozapine's features. One can classify these drugs on the basis of their in vitro pharmacological characteristics, [30] [31] [32] their neurophysiological actions, 33 their gene-induction profiles 34 or their actions in animal models. 35 However, all these schemes are based on preclinical characteristics of these medications. Suggested here is an alternative framework for classifying antipsychotics, derived from and based on the in vivo 5-HT 2 and D 2 occupancies of the antipsychotics at steady state at clinically relevant doses.
Classifying antipsychotics using the D 2 /5-HT 2 framework Figure 1 displays the criteria for classifying antipsychotics in this framework. Antipsychotics which show an average D 2 occupancy of Ͻ60%, at clinically relevant doses, are classified as 'low D 2 ' while those with a higher D 2 occupancy are 'high-D 2 '. This watershed of 60% is based on current evidence that at least 60% D 2 occupancy is required for antipsychotic response if that is the only mechanism invoked. 6 The next division of the drugs is along their 5HT 2 properties. Based on the review of evidence presented above, 25,31,36 drugs which show: (i) 5HT 2 occupancy Ͼ 80%; and (ii) 5-HT 2 occupancy greater than D 2 occupancy are classified as 'high-5HT 2 ', all others as 'low-5HT 2 .' Therefore a drug which has a 80% 5HT 2 occupancy, but also has a simultaneous 80% D 2 occupancy would not be a 'high-5HT 2 31 for a demonstration of this in the context of atypical antipsychotics). Second, the in vitro numbers do not account for the action of metabolites, which are often an important issue in the clinical situation. Third, the in vitro analyses usually do not account for competition with the endogenous agonist, a facet which affects all drug-receptor interactions in vivo. Finally, the in vitro affinity of a drug only tells of its 'potential' for occupying receptors. What matters clinically is not the potential, but the actual number of receptors occupied. For these reasons more meaningful comparisons can be made based on the effects of these drugs in vivo in humans (which factor in in vivo affinity, dose, metabolism, as well as human pharmacokinetics) at clinically relevant doses.
Useful attributes of this framework
The distinguishing attribute of this scheme is that it emanates from pharmacological and clinical observations in humans and is clearly operationalised and therefore testable. This framework readily accommodates the observed pre-clinical and clinical differences between the currently available antipsychotics. Antipsychotics in the high-D 2 low-5HT 2 cell all exhibit catalepsy in animals, show prolactin elevation in humans, exhibit EPS in the clinically relevant doses and are associated with a high risk of TD over prolonged usage. The low-D 2 high-5HT 2 group shows no (or minimal) catalepsy in animals, does not cause significant prolactin elevation and does not induce the classical Parkinsonian EPS and is not associated with TD. It is contended that these differences obtain directly from the different D 2 properties of these two groups. Furthermore, the low-D 2 high-5HT 2 group is known to be effective against negative symptoms and may be effective in a subset of refractory patients. Medications in the high-D 2 high-5HT 2 category do exhibit catalepsy in animals, prolactin elevation in humans and EPS (reflecting their high-D 2 status)-but in animals as well as in humans seem to exhibit a much wider margin between these side-effects and therapeutic efficacy (perhaps reflecting the modulation of these attributes by the presence of high-5HT 2 ).
Another value of this framework is in generating a hypothesis regarding the mechanism of action of antipsychotic drugs. A classification is of value only if members within a group share properties which make them distinct from members in other groups. It is predicted that all the drugs in a given cell in Figure 1 would exhibit similar properties with respect to the following attributes: (i) efficacy vs positive symptoms; (ii) efficacy vs negative symptoms; (iii) potential for causing catalepsy in animals, prolactin elevation in humans, Parkinsonian EPS in humans and TD with long-term use. If this prediction is wrong, that is, if we do find a drug which is in the same cell as clozapine, but substantially differs from clozapine along the above cited attributes, it would suggest that our current thoughts regarding 5-HT 2 /D 2 require modification. Pharmacological contrast of such a drug with clozapine would lead us to the source of clozapine's differential efficacy. Similarly, if a drug is found in the high-D 2 high-5HT 2 group which never gives prolactin elevation or EPS at all the clinical doses, that would defy this framework. But, pharmacological contrast of that drug with risperidone would point us to the neurotransmitter systems, beyond just D 2 and 5-HT 2 , which may be involved in protecting one from EPS and prolactin elevation.
Finally, at present, there are no antipsychotic treatments in the low-D 2 low-5HT cell. However, this is a very important cell. If we were to find a medication which shows antipsychotic benefits while in this cell (for example a predominant D 4 antagonist would fall in this cell), it would be a radical departure from the currently available treatments and may bring with it a new definition of antipsychotic treatment.
Limitations of this framework
Biological systems tend to be continuous rather than quantum, therefore, any effort to encapsulate nature into discrete divisions (such as Figure 1) is clearly an oversimplification. Nonetheless, these divisions are provided because they explain the current data, they are heuristically useful and provide a framework for generating testable hypotheses.
The major limitation of this scheme is that it only accommodates receptors which can be measured in humans. This is just a technical limitation. It is hoped that as our knowledge and interest in a particular receptor system evolves, the ability to measure them in vivo will develop in concert. A more salient limitation is that this framework deals with phenomena only at the cell-surface receptor level. Antipsychotic response lags behind the occupation of receptors. It is only logical to assume that biological changes at the post-receptor system are involved. At present little is known about which post-receptor changes are clinically relevant and there are few techniques to measure these in the living human brain. It is the author's view that receptor and post-receptor changes are complementary views of a cascade that effects antipsychotic response. Therefore, the four groups currently presented in Figure 1 would be expected to have distinct intracellular finger-prints. And our understanding of antipsychotic action would be advanced by mapping differences at the receptor levels (low-D 2 vs high-D 2 ) to their different consequences at the post-receptor level.
In summary, the first decade of in vivo human neuroreceptor imaging has produced interesting empirical regularities. This article has attempted to review these findings and impose on them a theoretical framework. While the proposed framework can accommodate most of the present findings, the real test lies in whether this framework can predict and accommodate new findings in this area. Have the PET data told us how antipsychotics work? Not really. Have they told us how and where to look for the answer? Perhaps yes.
